Clinical practice guideline for breast-conserving surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Title: Clinical practice guideline for breast-conserving surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
Edition: Original
Classification: Standard guideline
Field: Treatment
Countries and regions: China
Guidelines users: Clinicians specializing in breast diseases in China.
Evidence classification method: The level of evidence grading system was developed by referring to the GRADE system combined with findings in clinical studies in China. The levels are classified as Category I, II, III, and IV to quantify the evaluation of the reliability of the evidence by experts on the compiling committees. To make these guidelines accessible in clinical practice in China, the expert panel preferentially selected Category I and II evidence, as indicated in the guideline evaluation system
Development unit: 中华医学会外科学分会乳腺外科学组
Registration time: 2021-06-07
Registration number: IPGRP-2021CN139
Purpose of the guideline: Breast-conserving surgery (BCS) with radiotherapy is the primarily agreed surgical choice for eligible patients with an early diagnosis of breast cancer. In 2019, the panel of Chinese experts assembled by the Chinese Society for Breast Surgery (CSBrS) developed a Chinese experts’ consensus on BCS for early-stage breast cancer (Version 2019) with the aim of standardizing BCS in China. Subsequently, the CSBrS conducted a review of published reports and discussions between experts to determine the key clinical questions for the Clinical Practice Guideline for Breast-Conserving Surgery in Patients with Early-Stage Breast Cancer. The group evaluated the relevant evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system, and developed a Clinical Practice Guideline for Breast-Conserving Surgery in Patients with Early-Stage Breast Cancer (Version 2021), with the aim of providing guidance on clinical practice to breast surgeons in China.